Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00380224 · ClinicalTrials.gov registry record · Phase 3

Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.

A Phase 3 study of Schizophrenia, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 3
Development phase
120
Enrollment target
20
Study locations

NCT00380224 is a Phase 3 study of Schizophrenia that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 120 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00380224, a Phase 3 study of Schizophrenia, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

This study will compare bifeprunox to a currently marketed medication, Zyprexa (olanzapine), with respect to the affect on weight during the treatment of outpatients with schizophrenia. The study will compare the effect of these medications on several variables, including body weight and triglyceride levels.

Conditions Studied

Schizophrenia

Interventions

  • DRUG bifeprunox, olanzapine

Study Locations (20)

California

  • - Anaheim
  • - Anaheim
  • - Anaheim
  • - Boynton Beach
  • - Costa Mesa
  • - Costa Mesa
  • - Escondido
  • - Garden Grove
  • - Glendale
  • - Huntington Beach
  • - La Mesa
  • - National City
  • - Oceanside
  • - Paramount
  • - Rosemead
  • - San Diego
  • - San Diego
  • - San Diego

Arkansas

  • - Little Rock
  • - Little Rock

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2006-07
Est. Completion 2007-09
Phase Phase 3

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00380224

The ClinicalTrials.gov registry entry for NCT00380224 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (45% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which bifeprunox, olanzapine is the first listed.

NCT00380224 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00380224 about?

NCT00380224 is a clinical study titled "Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.". This study will compare bifeprunox to a currently marketed medication, Zyprexa (olanzapine), with respect to the affect on weight during the treatment of outpatients with schizophrenia. The study will compare the effect of these medications on several variables, including body weight and triglycerid...

What is the current status of trial NCT00380224?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2006-07. Estimated completion is 2007-09.

What conditions does trial NCT00380224 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT00380224?

The interventions under investigation include: bifeprunox, olanzapine (DRUG).

Who is sponsoring clinical trial NCT00380224?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00380224 being conducted?

This trial has 20 study locations across Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.